Discovery of Small Molecules That Induce Lysosomal Cell Death in Cancer Cell Lines Using an Image-Based Screening Platform

Assay and Drug Development Technologies

Volumn 14, Issue 8, 2016, Pages 489-510

  Pagliero, Romina J ^a   D'Astolfo, Diego S ^a,b   Lelieveld, Daphne ^a   Pratiwi, Riyona D ^a   Aits, Sonja ^c   Jaattela, Marja ^c   Martin, Nathaniel I ^d   Klumperman, Judith ^a   Egan, David A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HUBRECHT INSTITUTE   (Netherlands)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

galectin 3 reporter; high throughput screening; LMP phenotypic assay; lysosomal cell dead

Indexed keywords

ASTEMIZOLE; CASPASE 3; CHLORHEXIDINE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOMIFENE CITRATE; FLUPHENAZINE; GALECTIN 3; HOE 33342; LEVOMEPROMAZINE; METIXENE; PERPHENAZINE; PIPERACETAZINE; PRIMAQUINE; PROCHLORPERAZINE MALEATE; PROMAZINE; PROPIDIUM IODIDE; PROTEIN BCL 2; SERTINDOLE; SIRAMESINE; STAUROSPORINE; TAMOXIFEN CITRATE; TAMOXIFEN DERIVATIVE; THIETHYLPERAZINE MALEATE; THIORIDAZINE; TOREMIFENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNINDEXED DRUG; ZUCLOPENTHIXOL; INDOLE DERIVATIVE; MOLECULAR LIBRARY; SPIRO COMPOUND;

APOPTOSIS; ARTICLE; CALCEIN-AM ASSAY; CANCER CELL LINE; CELL DEATH; CELL DENSITY; CELL PERMEABILIZATION; CELL PH; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOSE RESPONSE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; LC50; LYSOSOME; PHENOTYPE; PLASMID; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; MCF-7 CELL LINE; MOLECULAR LIBRARY; PHARMACOLOGY; PHYSIOLOGY; PROCEDURES;

CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; LYSOSOMES; MCF-7 CELLS; SMALL MOLECULE LIBRARIES; SPIRO COMPOUNDS;

EID: 84991738403     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2016.727     Document Type: Article

References (62)

1. Brown JM, Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-237.
2. Jaattela M: Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004;23:2746-2756.
3. Yang J, Liu X, Bhalla K, et al. : Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132.
4. Groth-Pedersen L, Jaattela M: Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett 2013;332:265-274.
5. de Duve C: Lysosomes revisited. Eur J Biochem 1983;137:391-397.
6. Luzio JP, Pryor PR, Bright NA: Lysosomes: fusion and function. Nat Rev Mol Cell Biol 2007;8:622-632.
7. Reinheckel T, Deussing J, Roth W, Peters C: Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol Chem 2001;382:735-741.
8. Kroemer G, Jaattela M: Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005;5:886-897.
9. Appelqvist H, Waster P, Kagedal K, Ollinger K: The lysosome: from waste bag to potential therapeutic target. J Mol Cell Biol 2013;5:214-226.
10. Cesen MH, Pegan K, Spes A, Turk B: Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 2012;318:1245-1251.
11. Mrschtik M, Ryan KM: Lysosomal proteins in cell death and autophagy. FEBS J 2015;282:1858-1870.
12. Kirkegaard T, Jaattela M: Lysosomal involvement in cell death and cancer. Biochim Biophys Acta 2009;1793:746-754.
13. Stoka V, Turk V, Turk B: Lysosomal cysteine cathepsins: signaling pathways in apoptosis. Biol Chem 2007;388:555-560.
14. Aits S, Jaattela M: Lysosomal cell death at a glance. J Cell Sci 2013;126:1905-1912.
15. GuicciardiME, Leist M, GoresGJ: Lysosomes in cell death. Oncogene 2004;23:2881-2890.
16. De Stefanis D, Demoz M, Dragonetti A, et al. : Differentiation-induced changes in the content, secretion, and subcellular distribution of lysosomal cathepsins in the human colon cancer HT-29 cell line. Cell Tissue Res 1997;289:109-117.
17. Kallunki T, Olsen OD, Jaattela M: Cancer-associated lysosomal changes: friends or foes? Oncogene 2013;32:1995-2004.
18. Mohamed MM, Sloane BF: Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-775.
19. Fehrenbacher N, Bastholm L, Kirkegaard-Sorensen T, et al. : Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosomeassociated membrane proteins 1 and 2. Cancer Res 2008;68:6623-6633.
20. Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M: Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 2005;65:8975-8983.
21. Feng Y, Mitchison TJ, Bender A, Young DW, Tallarico JA: Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov 2009;8:567-578.
22. Carpenter AE: Image-based chemical screening. Nat Chem Biol 2007;3:461-465.
23. Nadanaciva S, Lu S, Gebhard DF, Jessen BA, Pennie WD, Will Y: A high content screening assay for identifying lysosomotropic compounds. Toxicol In Vitro 2011;25:715-723.
24. Lemieux B, Percival MD, Falgueyret JP: Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. Anal Biochem 2004;327:247-251.
25. Ostenfeld MS, Hoyer-Hansen M, Bastholm L, et al. : Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy 2008;4:487-499.
26. Aits S, Jaattela M, Nylandsted J: Methods for the quantification of lysosomal membrane permeabilization: a hallmark of lysosomal cell death. Methods Cell Biol 2015;126:261-285.
27. Paz I, Sachse M, Dupont N, et al. : Galectin-3, a marker for vacuole lysis by invasive pathogens. Cell Microbiol 2010;12:530-544.
28. Maejima I, Takahashi A, Omori H, et al. : Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J 2013;32: 2336-2347.
29. Freeman D, Cedillos R, Choyke S, et al. : Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013;8:e62143.
30. Thurston TL, Wandel MP, von Muhlinen N, Foeglein A, Randow F: Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 2012;482:414-418.
31. D'Astolfo DS, Pagliero RJ, Pras A, et al. : Efficient intracellular delivery of native proteins. Cell 2015;161:674-690.
32. Aits S, Kricker J, Liu B, et al. : Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay. Autophagy 2015;11:1408-1424.
33. Perregaard J, Moltzen EK, Meier E, Sanchez C. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles. J Med Chem 1995;38:1998-2008.
34. Sommer M, Nielsen O, SommerM: Methods formanufacture of dihydroisobenzofuran derivatives. US patent WO 2004/026855 A1, 2004.
35. Ellegaard AM, Groth-Pedersen L, Oorschot V, et al. : Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol Cancer Ther 2013;12:2018-2030.
36. Maier O, Marvin SA, Wodrich H, Campbell EM, Wiethoff CM: Spatiotemporal dynamics of adenovirus membrane rupture and endosomal escape. J Virol 2012;86:10821-10828.
37. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
38. Edwards BS, Ivnitski-Steele I, Young SM, Salas VM, Sklar LA: High-throughput cytotoxicity screening by propidium iodide staining. Curr Protoc Cytom 2007; Chapter 9:Unit9. 24.
39. Buenz EJ, Limburg PJ, Howe CL: A high-throughput 3-parameter flow cytometrybased cell death assay. Cytometry A 2007;71:170-173.
40. Feng J, Wang T, Zhang S, Shi W, Zhang Y: An optimized SYBR Green I/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferi. PLoS One 2014;9:e111809.
41. Janicke RU, Sprengart ML, Wati MR, Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357-9360.
42. Hwang J, Kim H, Kim J, et al. : Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. Biometals 2010;23:997-1013.
43. Kim LA, Amarnani D, Gnanaguru G, Tseng WA, Vavvas DG, D'Amore PA: Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms. Invest Ophthalmol Vis Sci 2014; 55:4747-4758.
44. Petersen NH, Olsen OD, Groth-Pedersen L, et al. : Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 2013;24:379-393.
45. Zong D, Zielinska-Chomej K, Juntti T, et al. : Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer. Cell Death Dis 2014;5:e1111.
46. Kornhuber J, Tripal P, Reichel M, et al. : Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 2008;51:219-237.
47. Antunes F, Cadenas E, Brunk UT: Apoptosis induced by exposure to a low steady-state concentration of H2O2 is a consequence of lysosomal rupture. Biochem J 2001;356:549-555.
48. Moriyama Y, Takano T, Ohkuma S: Acridine orange as a fluorescent probe for lysosomal proton pump. J Biochem 1982;92:1333-1336.
49. Varma H, Gangadhar NM, Letso RR, Wolpaw AJ, Sriramaratnam R, Stockwell BR: Identification of a smallmolecule that induces ATG5-and-cathepsin-l-dependent cell death and modulates polyglutamine toxicity. Exp Cell Res 2013;319:1759-1773.
50. Zong D, Haag P, Yakymovych I, Lewensohn R, Viktorsson K: Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of gammaH2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation. Cell Death Dis 2011;2:e181.
51. Sukhai MA, Prabha S, Hurren R, et al. : Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J Clin Invest 2013;123:315-328.
52. Kornhuber J, Tripal P, Reichel M, et al. : Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 2010;26:9-20.
53. Kreuger MR, Grootjans S, Biavatti MW, Vandenabeele P, D'Herde K: Sesquiterpene lactones as drugs with multiple targets in cancer treatment: focus on parthenolide. Anticancer Drugs 2012;23:883-896.
54. Kim SL, Liu YC, Seo SY, et al. : Parthenolide induces apoptosis in colitis-associated colon cancer, inhibiting NF-kappaB signaling. Oncol Lett 2015;9:2135-2142.
55. Wyrebska A, Gach K, Janecka A: Combined effect of parthenolide and various anti-cancer drugs or anticancer candidate substances on malignant cells in vitro and in vivo. Mini Rev Med Chem 2014;14:222-228.
56. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N: What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 2010;15: 668-678.
57. Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, et al. : Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 2005;49:176-182.
58. Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, Nylandsted J, Jaattela M: Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res 2007;67:2217-2225.
59. Groth-Pedersen L, Aits S, Corcelle-Termeau E, Petersen NH, Nylandsted J, Jaattela M: Identification of cytoskeleton-associated proteins essential for lysosomal stability and survival of human cancer cells. PLoS One 2012;7:e45381.
60. D'Anneo A, Carlisi D, Lauricella M, et al. : Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis 2013;4:e891.
61. Fehrenbacher N, Jaattela M: Lysosomes as targets for cancer therapy. Cancer Res 2005;65:2993-2995.
62. Fehrenbacher N, Gyrd-Hansen M, Poulsen B, et al. : Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res 2004; 64:5301-5310.